Literature DB >> 26607853

Peritoneal carcinomatosis with synchronous liver metastases from colorectal cancer: Who will benefit from complete cytoreductive surgery?

Jean-Baptiste Delhorme1, Laure Dupont-Kazma2, Pietro Addeo3, François Lefebvre4, Elhocine Triki5, Benoit Romain5, Nicolas Meyer4, Philippe Bachellier3, Serge Rohr5, Cécile Brigand5.   

Abstract

PURPOSE: Selection of patients for resection of synchronous liver metastases (LM) and peritoneal carcinomatosis (PC) of colorectal cancer (CRC) remains a debated issue since morbidity of this surgery is not negligible. We aimed to define overall survival (OS) prognostic criteria in patients undergoing PC surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) and LM resection.
METHODS: This monocentric and comparative study included all consecutive patients operated for LM (LM group, n = 77), PC (HIPEC group, n = 18) and PC + LM (LM + HIPEC group, n = 9) from January 2007 to May 2011. Characteristics of the 3 groups were prospectively collected and retrospectively compared.
RESULTS: Median follow-up was 56,5 months. Major morbidity and mortality were respectively 14% and 3%. Two-year disease free and overall survival rates were respectively 23% and 76%. There were significantly more Dindo grade III-IV complications in LM + HIPEC group. In multivariate analysis, grade II and III preoperative chemotherapy-induced toxicity and size of LM were identified as poor OS prognostic factors whereas response to preoperative chemotherapy significantly increases OS. OS was not different (p = 0.235) between the 3 groups.
CONCLUSION: Toxicity to preoperative chemotherapy and size of LM were identified as poor prognostic factors in patients undergoing simultaneous PC and LM surgery. These criteria could help in better selecting patients for such extensive surgery.
Copyright © 2015 IJS Publishing Group Limited. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Cytoreductive surgery; HIPEC; Liver metastasis; Liver resection; Peritoneal carcinomatosis

Mesh:

Substances:

Year:  2015        PMID: 26607853     DOI: 10.1016/j.ijsu.2015.11.025

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  7 in total

1.  Surgical dilemmas in the management of colorectal liver metastases: The role of timing.

Authors:  Dimitrios Dimitroulis; Gregory Kouraklis
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

2.  ASO Author Reflections: Synchronous Liver and Peritoneal Metastasis From Colorectal Cancer.

Authors:  Eyal Mor; Mohammad Adileh; Arie Ariche; Aviram Nissan
Journal:  Ann Surg Oncol       Date:  2020-10-01       Impact factor: 5.344

Review 3.  Metastatic Colorectal Cancer to the Peritoneum: Current Treatment Options.

Authors:  Nikolaos Vassos; Pompiliu Piso
Journal:  Curr Treat Options Oncol       Date:  2018-09-01

Review 4.  Therapeutic options for peritoneal metastasis arising from colorectal cancer.

Authors:  Gabriel Glockzin; Hans J Schlitt; Pompiliu Piso
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-08-06

5.  Impact of Synchronous Liver Resection on the Perioperative Outcomes of Patients Undergoing CRS-HIPEC.

Authors:  Jordan M Cloyd; Sherif Abdel-Misih; John Hays; Mary E Dillhoff; Timothy M Pawlik; Carl Schmidt
Journal:  J Gastrointest Surg       Date:  2018-04-30       Impact factor: 3.452

6.  Perioperative and Oncological Outcomes of Combined Hepatectomy with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer.

Authors:  Mohammad Adileh; Eyal Mor; Arie Ariche; Aviram Nissan; Dan Assaf; Haggai Benvenisti; Shachar Laks; Almog Ben-Yaacov; Gal Schtrechman; David Hazzan; Einat Shacham-Shmueli; Ofer Margalit; Naama Halpern; Dan Aderka; Daria Perelson
Journal:  Ann Surg Oncol       Date:  2020-09-23       Impact factor: 5.344

7.  Clinical outcomes of complete cytoreduction with concurrent liver resection followed by hyperthermic intraperitoneal chemotherapy for synchronous peritoneal and liver metastatic colorectal cancer.

Authors:  Youngbae Jeon; Eun Jung Park; Jin Hong Lim; Seung Hyuk Baik
Journal:  World J Surg Oncol       Date:  2019-12-11       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.